Oncternal gains on new cancer antibody drug data

Oncternal Therapeutics

27/05/2022 11:20

** Shares of drug developer Oncternal Therapeutics  ONCT.O 
rise 7% to $0.88 premarket
    ** ONCT late on Thursday reported new data from an ongoing
early- to mid-stage study of its antibody drug candidate,
zilovertamab, among patients with two types of blood cancers
affecting the immune system  urn:newsml:reuters.com:*:nGNX36Bmp4
    ** Zilovertamab in combination with AbbVie's  ABBV.N  drug 
ibrutinib showed cancer shrinkage in 85%, or 23 of 27, evaluable
patients with mantle cell lymphoma, said ONCT
    ** This compares favorably to the historical rate of 66% for
ibrutinib alone - ONCT
    ** Cancer shrinkage was observed in 91%, or 31 of 34,
evaluable patients with chronic lymphocytic leukemia receiving
the treatment; combination therapy well tolerated- Co
    ** Company to present the data at the American Society of
Clinical Oncology (ASCO) annual meeting on June 4
    **  Stock had plunged 63.9% YTD, as of its last close

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))